CA2960830C - Detection of misfolded proteins - Google Patents
Detection of misfolded proteins Download PDFInfo
- Publication number
- CA2960830C CA2960830C CA2960830A CA2960830A CA2960830C CA 2960830 C CA2960830 C CA 2960830C CA 2960830 A CA2960830 A CA 2960830A CA 2960830 A CA2960830 A CA 2960830A CA 2960830 C CA2960830 C CA 2960830C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- misfolded
- soluble
- incubation mixture
- incubation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 442
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 441
- 238000001514 detection method Methods 0.000 title description 29
- 238000011534 incubation Methods 0.000 claims abstract description 164
- 239000000203 mixture Substances 0.000 claims abstract description 163
- 238000000034 method Methods 0.000 claims abstract description 108
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 36
- 239000000523 sample Substances 0.000 claims description 128
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 65
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 claims description 47
- 238000013019 agitation Methods 0.000 claims description 28
- 239000013060 biological fluid Substances 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 25
- 210000002381 plasma Anatomy 0.000 claims description 23
- 125000004122 cyclic group Chemical group 0.000 claims description 19
- 238000011533 pre-incubation Methods 0.000 claims description 19
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 14
- 208000007153 proteostasis deficiencies Diseases 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 12
- -1 lymph Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000007990 PIPES buffer Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 6
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 6
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 6
- 239000007992 BES buffer Substances 0.000 claims description 6
- 239000007995 HEPES buffer Substances 0.000 claims description 6
- 239000007987 MES buffer Substances 0.000 claims description 6
- 239000007993 MOPS buffer Substances 0.000 claims description 6
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 6
- 239000007994 TES buffer Substances 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims description 5
- 210000004381 amniotic fluid Anatomy 0.000 claims description 5
- 210000003567 ascitic fluid Anatomy 0.000 claims description 5
- 210000000941 bile Anatomy 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000000416 exudates and transudate Anatomy 0.000 claims description 5
- 210000003608 fece Anatomy 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 210000002751 lymph Anatomy 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 210000003097 mucus Anatomy 0.000 claims description 5
- 210000004910 pleural fluid Anatomy 0.000 claims description 5
- 210000004915 pus Anatomy 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 210000002374 sebum Anatomy 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 210000004243 sweat Anatomy 0.000 claims description 5
- 210000001179 synovial fluid Anatomy 0.000 claims description 5
- 210000001138 tear Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 102000019355 Synuclein Human genes 0.000 claims description 4
- 108050006783 Synuclein Proteins 0.000 claims description 4
- 210000002939 cerumen Anatomy 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 108091006629 SLC13A2 Proteins 0.000 claims description 3
- 210000004379 membrane Anatomy 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 230000002776 aggregation Effects 0.000 abstract description 72
- 238000004220 aggregation Methods 0.000 abstract description 72
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 71
- 102000029797 Prion Human genes 0.000 abstract description 24
- 108091000054 Prion Proteins 0.000 abstract description 24
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 21
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 21
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 58
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 58
- 239000000178 monomer Substances 0.000 description 39
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 25
- 239000012071 phase Substances 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 238000003556 assay Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 108010026424 tau Proteins Proteins 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 102000013498 tau Proteins Human genes 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 239000011324 bead Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 230000013632 homeostatic process Effects 0.000 description 12
- 230000003941 amyloidogenesis Effects 0.000 description 11
- 238000003318 immunodepletion Methods 0.000 description 11
- 230000004770 neurodegeneration Effects 0.000 description 11
- 239000013610 patient sample Substances 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 9
- 208000024777 Prion disease Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 238000010899 nucleation Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 238000000527 sonication Methods 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 7
- 102000003802 alpha-Synuclein Human genes 0.000 description 7
- 108090000185 alpha-Synuclein Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000003412 degenerative effect Effects 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004962 physiological condition Effects 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000023105 Huntington disease Diseases 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 208000032859 Synucleinopathies Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000010200 folin Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000004848 nephelometry Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000003557 neuropsychological effect Effects 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 description 2
- KLFRZDOQQDHVSS-UHFFFAOYSA-N 2-[[5-[5-(4-hydroxyphenyl)thiophen-2-yl]thiophen-2-yl]methylidene]propanedinitrile Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=2SC(C=C(C#N)C#N)=CC=2)S1 KLFRZDOQQDHVSS-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102400000573 Amyloid-beta protein 40 Human genes 0.000 description 2
- 102400000574 Amyloid-beta protein 42 Human genes 0.000 description 2
- 102100021257 Beta-secretase 1 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 2
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 2
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 description 2
- 241000282943 Odocoileus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011979 disease modifying therapy Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 208000037957 feline spongiform encephalopathy Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920000123 polythiophene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000007111 proteostasis Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000008864 scrapie Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 1
- FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKDNQONLGXOZRG-HRNNMHKYSA-N CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 Chemical compound CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 WKDNQONLGXOZRG-HRNNMHKYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 101150097070 Drd3 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000867817 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1D Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000933173 Tragelaphus angasii Species 0.000 description 1
- 241000283904 Tragelaphus strepsiceros Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 102000003799 beta-Synuclein Human genes 0.000 description 1
- 108090000182 beta-Synuclein Proteins 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229950001954 crenezumab Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000010544 human prion disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007121 neuropathological change Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002776 polycyclohexyl methacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 108010084171 vanutide cridificar Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049306P | 2014-09-11 | 2014-09-11 | |
| US62/049,306 | 2014-09-11 | ||
| PCT/US2015/049844 WO2016040907A1 (en) | 2014-09-11 | 2015-09-11 | Detection of misfolded proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2960830A1 CA2960830A1 (en) | 2016-03-17 |
| CA2960830C true CA2960830C (en) | 2023-09-05 |
Family
ID=55454515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2960830A Active CA2960830C (en) | 2014-09-11 | 2015-09-11 | Detection of misfolded proteins |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160077112A1 (enExample) |
| EP (2) | EP3191599B1 (enExample) |
| JP (2) | JP6980953B2 (enExample) |
| KR (1) | KR102448128B1 (enExample) |
| CN (1) | CN107208125A (enExample) |
| AU (1) | AU2015314783B2 (enExample) |
| BR (1) | BR112017004899A2 (enExample) |
| CA (1) | CA2960830C (enExample) |
| ES (1) | ES2953855T3 (enExample) |
| HR (1) | HRP20231232T1 (enExample) |
| IL (2) | IL251052B (enExample) |
| MX (1) | MX2017003269A (enExample) |
| PL (1) | PL3191599T3 (enExample) |
| SG (2) | SG11201701953RA (enExample) |
| WO (1) | WO2016040907A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| US11079396B2 (en) * | 2019-09-04 | 2021-08-03 | Amprion, Inc. | Alpha-synuclein detection using beads |
| GB201611840D0 (en) * | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| CN110869763B (zh) * | 2017-05-16 | 2022-07-29 | 安培里翁公司 | 错误折叠tau蛋白质的检测 |
| US11313867B2 (en) | 2017-10-02 | 2022-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| CN111630382A (zh) * | 2017-12-21 | 2020-09-04 | H.隆德贝克有限公司 | α-共核蛋白病的测定、方法和治疗 |
| CN108088816A (zh) * | 2018-01-23 | 2018-05-29 | 深圳市国赛生物技术有限公司 | 小型特定蛋白分析仪 |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| WO2019222554A2 (en) * | 2018-05-16 | 2019-11-21 | Amprion, Inc. | Detection of brain injury or neurological disease using tau protein |
| CN112585686B (zh) | 2018-09-21 | 2024-07-09 | 渊慧科技有限公司 | 通过组合距离图裁剪来确定蛋白距离图 |
| JP7376040B2 (ja) * | 2019-09-03 | 2023-11-08 | 国立大学法人京都工芸繊維大学 | 神経変性疾患におけるバイオマーカー分子の検出方法 |
| KR102277871B1 (ko) * | 2019-12-17 | 2021-07-15 | 원광대학교산학협력단 | 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트 |
| WO2021198098A1 (en) | 2020-04-03 | 2021-10-07 | Universität Zürich | Improved method of detecting biomarkers in a biological sample |
| MX2022014319A (es) * | 2020-05-18 | 2023-02-27 | Amprion Inc | Sustratos de alfa-sinucleína y métodos para la fabricación y el uso de los mismos. |
| CA3199642A1 (en) * | 2020-11-21 | 2022-05-27 | Shuwen Biotech Co. Ltd. | Apparatus and method for detecting misfolded protein in biological sample |
| WO2022221876A1 (en) * | 2021-04-15 | 2022-10-20 | The Brigham And Women's Hospital, Inc. | Digital protein misfolding assays |
| CN114199875B (zh) * | 2022-02-18 | 2022-05-20 | 之江实验室 | 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60138146D1 (de) | 2000-07-07 | 2009-05-07 | Serono Lab | Frühdiagnose von konformationellen Erkrankungen |
| EP1366368A2 (en) | 2001-01-03 | 2003-12-03 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| EP1820806A1 (en) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinity regions |
| EP1853915B1 (en) * | 2005-02-15 | 2011-10-12 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
| CN101489566B (zh) * | 2006-05-19 | 2012-04-18 | 阿尔尼拉姆医药品有限公司 | Aha基因的RNAi调控及其治疗性应用 |
| US20080118938A1 (en) * | 2006-09-06 | 2008-05-22 | Lisbell Estrada | Methods and Compositions for the Detection of Protein Folding Disorders |
| JP2010043865A (ja) * | 2006-12-12 | 2010-02-25 | Olympus Corp | 異常型プリオンの検出方法 |
| CA2779565A1 (en) * | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment |
| US9133343B2 (en) * | 2009-11-30 | 2015-09-15 | Enzo Biochem, Inc. | Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications |
| US20130288389A1 (en) * | 2011-01-18 | 2013-10-31 | Prionics Ag | Methods for amplification and detection of prions |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| WO2016040903A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
-
2015
- 2015-09-11 BR BR112017004899A patent/BR112017004899A2/pt active Search and Examination
- 2015-09-11 AU AU2015314783A patent/AU2015314783B2/en active Active
- 2015-09-11 WO PCT/US2015/049844 patent/WO2016040907A1/en not_active Ceased
- 2015-09-11 HR HRP20231232TT patent/HRP20231232T1/hr unknown
- 2015-09-11 CA CA2960830A patent/CA2960830C/en active Active
- 2015-09-11 SG SG11201701953RA patent/SG11201701953RA/en unknown
- 2015-09-11 US US14/852,478 patent/US20160077112A1/en not_active Abandoned
- 2015-09-11 CN CN201580058606.3A patent/CN107208125A/zh active Pending
- 2015-09-11 PL PL15839278.7T patent/PL3191599T3/pl unknown
- 2015-09-11 EP EP15839278.7A patent/EP3191599B1/en active Active
- 2015-09-11 SG SG10202008464UA patent/SG10202008464UA/en unknown
- 2015-09-11 EP EP23189057.5A patent/EP4292654A3/en active Pending
- 2015-09-11 MX MX2017003269A patent/MX2017003269A/es unknown
- 2015-09-11 ES ES15839278T patent/ES2953855T3/es active Active
- 2015-09-11 KR KR1020177009707A patent/KR102448128B1/ko active Active
- 2015-09-11 JP JP2017533721A patent/JP6980953B2/ja active Active
-
2017
- 2017-03-09 IL IL251052A patent/IL251052B/en unknown
-
2021
- 2021-05-12 JP JP2021081274A patent/JP7104943B2/ja active Active
-
2022
- 2022-03-30 IL IL291809A patent/IL291809B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4292654A2 (en) | 2023-12-20 |
| JP2017530373A (ja) | 2017-10-12 |
| AU2015314783A1 (en) | 2017-04-27 |
| WO2016040907A1 (en) | 2016-03-17 |
| CN107208125A (zh) | 2017-09-26 |
| JP7104943B2 (ja) | 2022-07-22 |
| MX2017003269A (es) | 2017-12-04 |
| EP3191599C0 (en) | 2023-08-02 |
| HRP20231232T1 (hr) | 2024-01-19 |
| IL251052A0 (en) | 2017-04-30 |
| IL291809A (en) | 2022-06-01 |
| US20160077112A1 (en) | 2016-03-17 |
| KR20170103741A (ko) | 2017-09-13 |
| IL291809B2 (en) | 2023-06-01 |
| EP3191599B1 (en) | 2023-08-02 |
| EP4292654A3 (en) | 2024-01-03 |
| KR102448128B1 (ko) | 2022-09-27 |
| JP6980953B2 (ja) | 2021-12-15 |
| CA2960830A1 (en) | 2016-03-17 |
| PL3191599T3 (pl) | 2023-12-27 |
| IL251052B (en) | 2022-05-01 |
| AU2015314783B2 (en) | 2021-10-21 |
| SG11201701953RA (en) | 2017-04-27 |
| EP3191599A4 (en) | 2018-03-14 |
| ES2953855T3 (es) | 2023-11-16 |
| JP2022000629A (ja) | 2022-01-04 |
| SG10202008464UA (en) | 2020-10-29 |
| EP3191599A1 (en) | 2017-07-19 |
| BR112017004899A2 (pt) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2960830C (en) | Detection of misfolded proteins | |
| US20240219406A1 (en) | Detection of misfolded alpha synuclein protein | |
| US9910049B2 (en) | Detection of misfolded amyloid beta protein | |
| US20220137073A1 (en) | Detection of misfolded tau protein | |
| US20210102961A1 (en) | Detection of misfolded proteins | |
| HK40105178A (en) | Detection of misfolded proteins | |
| US20190137515A1 (en) | Methods for estimating misfolded protein concentration in fluids and tissue by quantitative pmca | |
| US20190353669A1 (en) | Detection of Brain Injury or Neurological Disease using Tau Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |